Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
August 09 2024 - 8:00AM
Business Wire
On track to initiate Part 2 in
September
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the
“Company”) reports interim results near the completion of Part
1 of its Deltacel-01 Phase 1 clinical trial. This trial is
evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic,
off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with
stage 4 metastatic non-small cell lung cancer (NSCLC) who have
failed to respond to standard therapies.
Based on data from the five patients evaluated for
Progression-Free Survival (PFS) in the long-term follow-up, Kiromic
has registered a PFS ranging from 2 to 8 months, with an average of
4.8 months.
No dose limiting toxicities (DLTs) have been reported by the
clinical site for patients that have completed the full course of
therapy. One patient was withdrawn from the study before completing
the full course of therapy due to an adverse event related to a
pre-existing co-morbidity and unrelated to Deltacel. Consequently,
this subject could not be evaluated for PFS.
Additionally, the sixth and last patient in Part 1 of the
Deltacel-01 study started treatment on August 6th.
“We are pleased to have completed enrollment in Part 1 of our
clinical trial. The favorable results of our GDT therapy,
particularly with respect to PFS, in the first two cohorts that
comprise Part 1 underscore the potential of Deltacel to treat solid
tumors, and we look forward to launching Part 2 of this study,”
said Pietro Bersani, Chief Executive Officer of Kiromic
BioPharma.
Kiromic expects to obtain early safety and tolerability outcomes
from the last enrolled patient in September and efficacy results in
early October. Kiromic is on track to initiate Part 2 of
Deltacel-01 in September.
About Deltacel-01
In Kiromic’s open-label Phase 1 clinical trial, titled “Phase 1
Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell
Infusions in Combination With Low Dose Radiotherapy in Subjects
With Stage 4 Metastatic Non-Small Cell Lung Cancer” (NCT06069570),
patients with stage 4 NSCLC will receive two intravenous infusions
of Deltacel™ with four courses of low-dose, localized radiation
over a 10-day period. The primary objective of the Deltacel-01
trial is to evaluate safety, while secondary measurements include
objective response, progression-free survival, overall survival,
time to progression, time to treatment response and disease control
rates.
About Deltacel™
Deltacel™ (KB-GDT-01) is an investigational gamma delta T-cell
(GDT) therapy currently in the Deltacel-01 Phase 1 trial for the
treatment of stage 4 metastatic NSCLC. An allogeneic product
consisting of unmodified, donor-derived gamma delta T cells,
Deltacel™ is the leading candidate in Kiromic’s GDT platform.
Deltacel™ is designed to exploit the natural potency of GDT cells
to target solid cancers, with an initial clinical focus on NSCLC,
which represents about 80% to 85% of all lung cancer cases. Data
from two preclinical studies demonstrated Deltacel™’s favorable
safety and efficacy profile when it was combined with low-dose
radiation.
About Kiromic BioPharma
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated
biotherapeutics company using its proprietary DIAMOND® artificial
intelligence (AI) 2.0 target discovery engine to develop and
commercialize cell therapies focusing on immuno-oncology. Kiromic
is developing a multi-indication allogeneic cell therapy platform
that exploits the natural potency of Gamma Delta T-cells to target
solid tumors. Kiromic’s DIAMOND® AI is where data science meets
target identification to dramatically compress the years and
hundreds of millions of dollars required to develop a live drug.
The Company maintains offices in Houston, Texas. To learn more,
visit www.kiromic.com and connect with us on Twitter and
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Kiromic makes such
forward-looking statements pursuant to the safe harbor provisions
of the United States Private Securities Litigation Reform Act,
Section 21E of the Securities Exchange Act of 1934, as amended, and
other federal securities laws. All statements other than statements
of historical facts are forward-looking statements. In some cases,
you can identify forward-looking statements by terms such as:
“will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
or the negative of these terms or other comparable terminology.
These forward-looking statements include, but are not limited to,
statements regarding: Kiromic’s ability to achieve its objectives
and Kiromic’s financing strategy and availability of funds. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
levels of activity, performance, or achievements to be materially
different from the information expressed or implied expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks and
uncertainties discussed in our Annual Report on Form 10-K for the
year ended December 31, 2023, and as detailed from time to time in
our other SEC filings. You should not rely upon forward-looking
statements as predictions of future events. Although we believe
that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee that the future results, levels
of activity, performance, or events and circumstances reflected in
the forward-looking statements will be achieved or occur. Moreover,
neither we nor any other person assumes responsibility for the
accuracy and completeness of the forward-looking statements. Such
forward-looking statements relate only to events as of the date of
this press release. We undertake no obligation to update any
forward-looking statements except to the extent required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240809927283/en/
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
212-201-6614
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Dec 2023 to Dec 2024